Sign in
Taking people in United StatesNo phase

Tests acupuncture for pain in people with sickle cell disease

Tests needle and laser acupuncture for pain in people with sickle cell disease.

Key facts

Who runs it
University of Cincinnati
Where
Cincinnati, United StatesSee the site
Trial code
Registry title
Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0
Status
Recruiting
People taking part
120 people, planned
Started
1 Jul 2026
Expected to end
28 Jun 2031
Type of study
Interventional, 4 groups
Treatments tested
  • needling acupuncture
  • laser acupuncture
Record updated
12 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for teenagers and adults with sickle cell disease who have long-lasting pain or painful crises. It tests acupuncture for pain.

Age
14 to 80 years old (14-17 adolescents, 18-80 adults).
Sex
All genders can join.
Disease stage
Diagnosed sickle cell disease (SS, SC or other type) with chronic pain in the past 6 months or a vaso-occlusive crisis in the past 12 months.
Earlier treatment
Pain medicines and sickle cell treatments are allowed but not required. People cannot have had acupuncture or related pain treatment in the last 6 months.

Main reasons for not taking part

  • Known bleeding or clotting problem, such as low platelets, that makes acupuncture unsafe
  • Another autoimmune or inflammatory disease, or another chronic pain condition worse than sickle pain
  • Pregnant or nursing
  • Cannot have MRI scans because of metal implants, seizure disorders or similar reasons
  • COVID-19 suspected or confirmed

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Any gender
  • 14-17 (Adolescents) and 18-80 (Adults) years old
  • Right-handed
  • Either outpatient or inpatient or status changing between each other
  • Have been diagnosed with SCD (includes but not limited to SS, SC or other type) and experiencing chronic pain in the past 6 months or vaso-occlusive crisis (VOC) in the past 12 months
  • Analgesic therapy prescribed by primary hematologists (or physicians for emergency or primary care) including pain-relieving medications (e.g. Morphine, coderin, Fentanyl, Oxycodone), Hydroxyurea (e.g. Droxia, Hydrea, Siklos), L-glutamine oral powder (Endari), Crizanlizumab (Adakveo), Voxelotor (Oxbryta), and/or other palliative treatment allowed, not required
  • Willing to limit the current and the introduction of any new medications or treatment modalities for control of pain symptoms during the study visits
  • Able to travel to the study site for participating scheduled visits (questionnaires, QST, EEG and MRI) and receive acupuncture treatments up to two times weekly for 5 weeks as scheduled
  • We will recruit without regard to ethnicity, however, due to the genetic nature of SCD, subjects will primarily be African-American or of African descent, although there are individuals with SCD who come from Hispanic, southern European, Middle Eastern, or Asian Indian backgrounds. The ethnic distribution in our prior studies is 95% Black/African American with 5% Hispanic or Latino (of any race). As these are minority groups many individuals may be from lower income situations
  • Fluent in English and capable of giving written informed consent

Who cannot take part

  • Presence of a concurrent autoimmune or inflammatory disease such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, etc. that causes pain or any other chronic pain condition with pain greater than sickle pain
  • Medication:; Recent (30 days) initiation or dose adjustment of stimulant medications, such as those used to treat ADD/ADHD (e.g., amphetamine/dextroamphetamine [Adderall®], methylphenidate, dextroamphetamine), or the fatigue associated with sleep apnea or shift work (e.g., modafinil)
  • History vascular surgery in lower limbs or current lower limb vascular dysfunction will not receive conditioned pressure pain stimuli in the lower limb
  • Subjects with Worker's Compensation, Workman's Compensation, civil litigation or disability claims pertinent to the subject's sickle disease; current involvement in out-of-court settlements for claims pertinent to the subject's sickle disease; or currently receiving monetary compensation as a result of any of the above
  • Participation of other studies: Concurrent participation in other therapeutic trials with overlapping research purposes
  • Subjects with Covid-19 suspicion or confirmation
  • Diseases/conditions history includes but not limited to:; head injury with substantial loss of consciousness; peripheral neuropathy of known cause that interferes with activities of daily living; known non-SCD related Severe psychiatric illnesses (e.g. current schizophrenia, major depression with suicidal ideation); significant visual, motor, or auditory impairment that would interfere with ability to perform study visits-related activities
  • Contraindications to MRI scans includes but are not limited to: surgical clips, surgical staples, metal implants, cardiac rhythmic disorders, seizure disorders, and certain metallic dental material will not be scheduled for MRI visits
  • Presence of a known coagulation abnormality: Thrombocytopenia (mild thrombocytopenia with a platelets range of 51,000-100,000/ul will be further evaluated for inclusion consideration), or bleeding diathesis that may preclude the safe use of acupuncture
  • Recent/ongoing alternative pain management with acupuncture or acupuncture-related techniques within the last 6-months
  • Pregnant or nursing

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 14 and 80 years old?

Where in United States

  • University of Cincinnati College of MedicineCincinnati, United StatesContact: Ying Wang, MD, PhDTaking people

About the trial

What the trial wants to find out

The proposed research is to determine the clinical efficacy and neurobiological mechanisms of acupuncture analgesia in patients with sickle cell disease.

The 4 groups in the trial

  • Needling Acupuncture - 5 weeksTreatment being tested

    Needling acupuncture treatment will last 30 minutes per session and will be administered two times per week for 5 weeks. Each subject will receive one course of treatment which contains 10 treatment sessions.

    Treatment: needling acupuncture

  • Laser Acupuncture - 5 weeksTreatment being tested

    Laser acupuncture treatment will also last 30 minutes per session and will be administered two times per week for 5 weeks. Each subject will receive one course of laser acupuncture treatment which contains 10 treatment sessions.

    Treatment: laser acupuncture

  • Needling Acupuncture - 12 weeksTreatment being tested

    Needling acupuncture treatment will last 30 minutes per session and will be administered once per week for 12 weeks. Each subject will receive one course of treatment which contains 12 treatment sessions.

    Treatment: needling acupuncture

  • Laser Acupuncture - 12 weeksTreatment being tested

    Laser acupuncture treatment will also last 30 minutes per session and will be administered once per week for 12 weeks. Each subject will receive one course of laser acupuncture treatment which contains 12 treatment sessions.

    Treatment: laser acupuncture

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Integrative Medicine in Pain Management in Sickle Cell Disease: Assessing the Clinical Efficacy and Neurobiological Impact With Acupuncture, 2.0
Plain-language title
Tests acupuncture for pain in people with sickle cell diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06725550, who can take part
Record updated
12 August 2026